• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Abpro Holdings Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    4/24/25 4:15:33 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABP alert in real time by email
    false 0001893219 0001893219 2025-04-20 2025-04-20 0001893219 ABP:SharesOfCommonStockParValue0.0001PerShareMember 2025-04-20 2025-04-20 0001893219 ABP:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member 2025-04-20 2025-04-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): April 20, 2025

     

    Abpro Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41224   87-1013956
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)  

    (I.R.S. Employer

    Identification No.)

     

    68 Cummings Park Drive

    Woburn, MA

      01801
    (Address of principal executive offices)   (Zip Code)

     

    1-800-396-5890

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
    Shares of Common Stock, par value $0.0001 per share   ABP   The Nasdaq Stock Market LLC
    Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50   ABPWW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry into Material Definitive Agreement.

     

    As previously disclosed, on November 13, 2024, pursuant to the previously disclosed Standby Equity Purchase Agreement dated October 30, 2024 with YA II PN, LTD (“Yorkville”), Abpro Holdings, Inc. (the “Company”), entered into a Convertible Promissory Note (“Yorkville Note”) for $3,000,000, and received net proceeds of $2,755,000. Unless otherwise defined herein, capitalized terms used in this Current Report on Form 8-K have the same meaning as set forth in the Yorkville Note.

     

    On April 20, 2025, the Company and Yorkville entered into Amendment No. 1 to Convertible Promissory Note (the “Amendment”) to amend the Yorkville Note, solely to amend and restate the definition of “Conversion Price” in the Yorkville Note to correct a scrivener’s error. Pursuant to the Amendment, “Conversion Price” means, “as of any Conversion Date or other date of determination, the lower of (i) $11.50 per Common Share (the “Fixed Price”), or (ii) 94% of the lowest daily VWAP during the 5 consecutive Trading Days immediately preceding the Conversion Date or other date of determination (the “Variable Price”), but which Variable Price shall not be lower than the Floor Price then in effect. The Fixed Price shall be adjusted (downwards only) to equal the VWAP of the Common Shares over the three (3) Trading Days immediately preceding the 20th Trading Day following the Issuance Date if such price is lower than the initial Fixed Price. The Conversion Price shall be adjusted from time to time pursuant to the other terms and conditions of this Note.” All other terms of the Yorkville Note remain unchanged.

     

    The foregoing description of the Amendment is subject to and qualified in its entirety by reference to the full text of the Amendment, a copy of which is included as Exhibit 10.1 hereto, and the terms of which are incorporated by reference.

     

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    10.1   Amendment No. 1 to Convertible Promissory Note, dated April 20, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ABPRO HOLDINGS, INC.
         
      By: /s/ Miles Suk
      Name:  Miles Suk
      Title: Chief Executive Officer
         
    Dated: April 24, 2025    

     

     

    2

     

     

    Get the next $ABP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ABP
    Leadership Updates

    Live Leadership Updates

    See more
    • Abpro Statement on the Departure of Former CEO Ian Chan

      WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, "As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully co

      3/10/25 6:34:55 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

      Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profileAbpro and Celltrion have a strategic partnership for worldwide development and commercialization of ABP-102/CT-P72HER2-positive cancers represent up to 30 percent of all cases of breast, gastric, pancreatic, colorectal and other forms of cancer WOBURN, Mass., April 27, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, and Celltrion, a leading biopharmaceutical company, today unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the

      4/27/25 2:00:00 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

      WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102/CT-P72 at the American Association for Cancer ResearchⓇ Annual Meeting 2025 ("AACR 2025") in the New Drugs on the Horizon session. AACR 2025 is taking place April 25-30, at the McCormick Place Convention Center in Chicago. Invited speaker presentation details Title:ABP-102/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with

      3/25/25 4:30:18 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abpro Statement on the Departure of Former CEO Ian Chan

      WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, "As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully co

      3/10/25 6:34:55 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman Suk Jin Wook (Miles) bought $4,212 worth of shares (16,200 units at $0.26), increasing direct ownership by 12% to 146,477 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      5/19/25 8:37:52 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Suk Jin Wook (Miles) bought $1,081 worth of shares (4,325 units at $0.25), increasing direct ownership by 3% to 130,277 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      5/1/25 4:21:30 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Suk Jin Wook (Miles) bought $11,113 worth of shares (34,002 units at $0.33), increasing direct ownership by 37% to 125,902 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      4/25/25 4:58:51 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman Suk Jin Wook (Miles) bought $4,212 worth of shares (16,200 units at $0.26), increasing direct ownership by 12% to 146,477 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      5/19/25 8:37:52 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Suk Jin Wook (Miles) bought $1,081 worth of shares (4,325 units at $0.25), increasing direct ownership by 3% to 130,277 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      5/1/25 4:21:30 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Suk Jin Wook (Miles) bought $11,113 worth of shares (34,002 units at $0.33), increasing direct ownership by 37% to 125,902 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      4/25/25 4:58:51 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABP
    SEC Filings

    See more
    • SEC Form 424B3 filed by Abpro Holdings Inc

      424B3 - Abpro Holdings, Inc. (0001893219) (Filer)

      5/15/25 5:25:47 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Abpro Holdings Inc

      10-Q - Abpro Holdings, Inc. (0001893219) (Filer)

      5/15/25 4:49:25 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Abpro Holdings Inc

      EFFECT - Abpro Holdings, Inc. (0001893219) (Filer)

      5/6/25 12:15:38 AM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care